查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美微生物組治療市場預測至 2030 年 - 區域分析 - 按類型、應用和最終用戶
市場調查報告書
商品編碼
1494520

北美微生物組治療市場預測至 2030 年 - 區域分析 - 按類型、應用和最終用戶

North America Microbiome Therapeutics Market Forecast to 2030 - Regional Analysis - by Type, Application, and End User
出版日期: | 出版商: The Insight Partners | 英文 68 Pages | 訂單完成後即時交付

價格

2022年北美微生物組治療市值為1.6164億美元，預計2030年將達到3.4299億美元；預計2022年至2030年複合年成長率為9.9%。

改善微生物組發現管道的資金流入推動北美微生物組治療市場

研究表明，微生物群的不平衡或破壞可能導致多種疾病，例如發炎性腸道疾病和肥胖，以及精神健康障礙。微生物組在整體健康中的作用的認知引起了人們對開發針對和調節微生物組的療法的濃厚興趣。此外，技術和研究工具的進步使得研究和操縱微生物組變得更加容易。新一代定序和宏基因組分析使人們能夠更深入地了解微生物群落及其功能。知識的增加為開發標靶療法開啟了新的可能性。美國食品藥物管理局（FDA）等監管機構也表示願意支持微生物療法的開發。 FDA 制定了 FMT 指南，並表示有興趣透過確保安全性和有效性的監管途徑來推進該領域的發展。所有這些因素結合起來，為微生物組治療領域的公司創造了有利的投資環境。

隨著強力的臨床證據的出現，投資人開始注意到微生物組調節劑公司。增加的資金為公司提供了必要的資源，以克服與開發和生產高成本相關的挑戰，最終推動該領域向前發展。

北美微生物組治療市場概述

人們越來越了解人類微生物組在維持健康和預防疾病方面的重要性，促使美國研究人員探索基於微生物組的干涉措施，將其作為治療各種疾病的有前景的方法。此外，該國在北美微生物組治療市場的主導地位主要歸功於其發達的研究基礎設施，有利於創新療法的開發此外，肥胖和炎症性腸道疾病等慢性病患病率的上升創造了需求創新治療，刺激微生物組療法的發展。基因定序和生物資訊學的技術進步使得微生物組的研究和改變成為可能，從而促進基於微生物組的個人化干涉措施的發展。個人化醫療的趨勢與客製化微生物組療法非常吻合。學術界、工業界和政府組織之間的合作也正在推動研究和開發工作，加速將科學發現轉化為商業產品。由於監管機構認知到微生物組療法的潛力並為其開發和批准提供指導，該領域的監管支持和投資進一步促進了市場成長。

北美微生物組治療市場收入及 2030 年預測（百萬美元）

北美微生物組治療市場細分

北美微生物組治療市場根據類型、應用、最終用戶和國家進行細分。

根據類型，北美微生物組治療市場分為治療方法和手術方法。到 2022 年，手術細分市場將佔據更大佔有率。

根據應用，北美微生物組治療市場分為代謝紊亂和肥胖、艱難梭菌感染、發炎性腸道疾病等。 2022 年，艱難梭菌感染部分佔最大佔有率。

從最終用戶來看，北美微生物組治療市場包括醫院和診所、門診手術中心、家庭護理等。 2022 年，醫院和診所領域佔最大佔有率。

根據國家/地區，北美微生物組治療市場分為美國、加拿大和墨西哥。 2022 年，美國將主導北美微生物組治療市場。

AOBiome Therapeutics Inc、Ferring Holdings SA、Finch Therapeutics Group Inc、Pendulum Therapeutics Inc 和 Seres Therapeutics Inc 是北美微生物組治療市場上的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 重要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：北美微生物組治療市場格局

  • 概述
  • 北美 PEST 分析

第 5 章：北美微生物組治療市場 - 主要產業動態

  • 北美微生物組治療市場 - 主要產業動態
  • 主要市場促進因素
    • 腸道微生物群在維持人類健康的潛力
    • 資金流入改善微生物組發現管道
  • 主要市場限制
    • 開發和生產成本高
  • 主要市場機會
    • 加強研發以更了解人類微生物組
  • 未來主要趨勢
    • 人類微生物組治療的技術進步
  • 促進因素和限制的影響：

第 6 章：微生物組治療市場 - 北美市場分析

第 7 章：北美微生物組治療市場分析 - 類型

  • 療法
    • 概述
    • 治療市場、收入與 2030 年預測
  • 程式
    • 概述
    • 程序市場、收入與 2030 年預測

第 8 章：北美微生物組治療市場分析 - 應用

  • 代謝紊亂與肥胖
    • 概述
    • 代謝紊亂和肥胖市場、收入和 2030 年預測
  • C. 艱難梭菌感染 (CDI)
    • 概述
    • C. 艱難梭菌感染 (CDI) 市場、收入和 2030 年預測
  • 發炎性腸道疾病
    • 概述
    • 發炎性腸道疾病市場、收入和 2030 年預測
  • 其他
    • 概述
    • 其他市場、收入和 2030 年預測

第 9 章：北美微生物組治療市場分析 - 最終用戶

  • 醫院和診所
    • 概述
    • 醫院和診所市場、收入和 2030 年預測
  • 門診手術中心
    • 概述
    • 門診手術中心市場、收入與 2030 年預測
  • 居家護理
    • 概述
    • 家庭護理市場、收入和 2030 年預測
  • 其他
    • 概述
    • 其他市場、收入和 2030 年預測

第 10 章：北美微生物組治療市場 - 國家分析

  • 美國
  • 加拿大
  • 墨西哥

第 11 章：產業格局

  • 概述
  • 北美微生物組治療市場的成長策略

第 12 章：公司簡介

  • Ferring Holdings SA
  • Vedanta Biosciences Inc
  • Finch Therapeutics Group Inc
  • Pendulum Therapeutics Inc
  • Seres Therapeutics Inc
  • AOBiome Therapeutics Inc

第 13 章：附錄

Product Code: BMIRE00029954

The North America microbiome therapeutics market was valued at US$ 161.64 million in 2022 and is expected to reach US$ 342.99 million by 2030; it is estimated to record a CAGR of 9.9% from 2022 to 2030.

Inflow of Funds to Ameliorate Microbiome Discovery Pipeline Drives North America Microbiome Therapeutics Market

Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome's role in overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. Regulatory agencies such as the US Food and Drug Administration (FDA) have also shown a willingness to support the development of microbiome therapeutics. The FDA has established guidelines for FMT and has expressed interest in advancing the field through regulatory pathways that ensure safety and efficacy. All these factors combined have created a favorable investment climate for companies working in the field of microbiome therapeutics.

As strong clinical evidence becomes available, investors are beginning to take notice of microbiome modulator firms. The heightened funding provides companies with necessary resources to overcome the challenges associated with the high cost of development and production, ultimately driving the field forward.

North America Microbiome Therapeutics Market Overview

The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treating various conditions. Additionally, the dominance of this country in the North America microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments Further, the rising prevalence of chronic diseases such as obesity and inflammatory bowel disease has created a demand for innovative treatments, spurring the development of microbiome therapeutics. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics. Collaborations between academia, industry, and government organizations are also fueling research and development efforts, accelerating the translation of scientific discoveries into commercial products. Regulatory support and investment in the field further contribute to market growth, as regulatory bodies recognize the potential of microbiome therapeutics and provide guidance for their development and approval.

North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

North America Microbiome Therapeutics Market Segmentation

The North America microbiome therapeutics market is segmented based on type, application, end user, and country.

Based on type, the North America microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held a larger share in 2022. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.

By application, the North America microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The C. difficile infection segment held the largest share in 2022.

By end user, the North America microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held the largest share in 2022.

Based on country, the North America microbiome therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America microbiome therapeutics market in 2022.

AOBiome Therapeutics Inc, Ferring Holdings SA, Finch Therapeutics Group Inc, Pendulum Therapeutics Inc, and Seres Therapeutics Inc are some of the leading companies operating in the North America microbiome therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Microbiome Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 North America PEST Analysis

5. North America Microbiome Therapeutics Market - Key Industry Dynamics

  • 5.1 North America Microbiome Therapeutics Market - Key Industry Dynamics
  • 5.2 Key Market Drivers
    • 5.2.1 Potential of Gut Microbiota in Maintaining Human Health
    • 5.2.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
  • 5.3 Key Market Restraints
    • 5.3.1 High Cost of Development and Production
  • 5.4 Key Market Opportunities
    • 5.4.1 Increasing R&D to Gain Better Understanding of Human Microbiome
  • 5.5 Key Future Trends
    • 5.5.1 Technological Advancement in Human Microbiome Therapeutics
  • 5.6 Impact of Drivers and Restraints:

6. Microbiome Therapeutics Market - North America Market Analysis

7. North America Microbiome Therapeutics Market Analysis - Type

  • 7.1 Therapeutics
    • 7.1.1 Overview
    • 7.1.2 Therapeutics Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 7.2 Procedure
    • 7.2.1 Overview
    • 7.2.2 Procedure Market, Revenue and Forecast to 2030 (US$ Thousand)

8. North America Microbiome Therapeutics Market Analysis - Application

  • 8.1 Metabolic Disorder and Obesity
    • 8.1.1 Overview
    • 8.1.2 Metabolic Disorder and Obesity Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.2 C. Difficile Infection (CDI)
    • 8.2.1 Overview
    • 8.2.2 C. Difficile Infection (CDI) Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.3 Inflammatory Bowel Disease
    • 8.3.1 Overview
    • 8.3.2 Inflammatory Bowel Disease Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

9. North America Microbiome Therapeutics Market Analysis - End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Overview
    • 9.1.2 Hospitals and Clinics Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.2 Ambulatory Surgical Centers
    • 9.2.1 Overview
    • 9.2.2 Ambulatory Surgical Centers Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.3 Homecare
    • 9.3.1 Overview
    • 9.3.2 Homecare Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

10. North America Microbiome Therapeutics Market - Country Analysis

  • 10.1 North America Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
    • 10.1.1 North America Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
    • 10.1.2 US
      • 10.1.2.1 US: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.2.2 US: North America Microbiome Therapeutics Market Breakdown by Type
        • 10.1.2.2.1 US North America Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.2.3 US: North America Microbiome Therapeutics Market Breakdown by Application
      • 10.1.2.4 US: North America Microbiome Therapeutics Market Breakdown by End User
    • 10.1.3 Canada
      • 10.1.3.1 Canada: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.3.2 Canada: North America Microbiome Therapeutics Market Breakdown by Type
        • 10.1.3.2.1 Canada North America Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.3.3 Canada: North America Microbiome Therapeutics Market Breakdown by Application
      • 10.1.3.4 Canada: North America Microbiome Therapeutics Market Breakdown by End User
    • 10.1.4 Mexico
      • 10.1.4.1 Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.4.2 Mexico: North America Microbiome Therapeutics Market Breakdown by Type
        • 10.1.4.2.1 Mexico: North America Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.4.3 Mexico: North America Microbiome Therapeutics Market Breakdown by Application
      • 10.1.4.4 Mexico: North America Microbiome Therapeutics Market Breakdown by End User

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in North America Microbiome Therapeutics Market

12. Company Profiles

  • 12.1 Ferring Holdings SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Vedanta Biosciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Finch Therapeutics Group Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Pendulum Therapeutics Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Seres Therapeutics Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 AOBiome Therapeutics Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. North America Microbiome Therapeutics Market Segmentation
  • Table 2. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - Type
  • Table 3. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - Therapeutics
  • Table 4. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - Application
  • Table 5. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) - End User
  • Table 6. North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Country
  • Table 7. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 8. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 9. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 10. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 11. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 12. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 13. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 14. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 15. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 16. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 17. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 18. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 19. Recent Growth Strategies in North America Microbiome Therapeutics Market
  • Table 20. Glossary of Terms, North America Microbiome Therapeutics Market

List Of Figures

  • Figure 1. North America Microbiome Therapeutics Market Segmentation, By Country
  • Figure 2. North America PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Microbiome Therapeutics Market Revenue (US$ Thousand), 2022 - 2030
  • Figure 5. North America Microbiome Therapeutics Market Share (%) - Type, 2022 and 2030
  • Figure 6. Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 7. Procedure Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 8. North America Microbiome Therapeutics Market Share (%) - Application, 2022 and 2030
  • Figure 9. Metabolic Disorder and Obesity Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 10. C. Difficile Infection (CDI) Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 11. Inflammatory Bowel Disease Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 12. Others Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 13. North America Microbiome Therapeutics Market Share (%) - End User, 2022 and 2030
  • Figure 14. Hospitals and Clinics Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 15. Ambulatory Surgical Centers Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 16. Homecare Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 17. Others Market Revenue and Forecasts to 2030 (US$ Thousand)
  • Figure 18. North America Microbiome Therapeutics Market Breakdown by Key Countries - Revenue (2022) (US$ Thousand)
  • Figure 19. North America Microbiome Therapeutics Market Breakdown by Key Countries, 2022 and 2030 (%)
  • Figure 20. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 21. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 22. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)